Table 1

Summary table of results for predicted prevalence estimates

CountryDrugMarginal rateRate among RSRate among RR
Malawi (n=1306)inh0.0599347730.0591702380.953801243
pza0.0023126890.001437480.604323538
levo0.3322295130.0009874950.04591181
eth0.0015612750.0014335520.591521511
amk0.0011535720.0012197030.053332609
Peru (n=1521)inh0.7857279620.3198831650.998016335
pza0.5107829210.0122952950.769380662
levo0.0140061690.0034338350.025017803
eth0.1003539090.0077566870.275508661
amk0.1311650410.0030211120.20217046
South Africa (n=3134)inh0.0894738060.0119214940.744976366
pza0.0465869380.0009070210.529110114
levo0.0042374150.0005267190.115334441
eth0.3319806350.0006818810.483917188
amk0.033516610.0006181030.321291162
UK (n=2831)inh0.1705457070.076913680.994410445
pza0.0709641510.0071971030.566614186
levo0.0035133190.0010422140.059629102
eth0.0011272710.0009213680.032878898
amk0.0101856390.0007676180.136479073
Viet Nam (n=1338)inh0.2440194390.245184510.973428345
pza0.0118438120.0031587740.441460286
levo0.0027091380.0024901060.032201895
eth0.0022776540.0023393510.041001766
amk0.0011490330.0012056020.023756816
  • The first column indicates the country and number of input isolates, remaining columns are as follows: mean resistance rate estimate after Gibbs bias-correction and outbreak correction (reported as per cent), mean resistance rate estimate among rifampin-resistant (RR) isolates after outbreak correction (reported as per cent), mean resistance rate estimate among rifampin susceptible (RS) isolates after outbreak correction (reported as per cent). Top five countries chosen based on most input isolate sequences of greater or equal to 1306 isolates.

  • amk, amikacin; eth, ethionamide; inh, isoniazid; levo, levofloxacin; pza, pyrazinamide.